Enhanced invasive properties exhibited by smooth muscle cells are associated with elevated production of MMP-2 in patients with aortic aneurysms.
BACKGROUND
abdominal aortic aneurysms (AAA) are associated with excessive vascular matrix remodelling. Recent findings suggest a systemic overproduction of matrix metalloproteinases-2 (MMP-2) by vascular smooth muscle cells (SMC) may be pivotal aetiologically. SMC migration is facilitated by MMP mediated proteolysis of the basement membrane and extracellular matrix. Our aim was to see if enhanced MMP-2 production by these SMC exhibit increased invasion, in an in vitro model of migration.


METHODS
SMC were derived from inferior mesenteric vein (IMV) harvested from patients undergoing aneurysm repair (n=6) or colectomy for diverticulosis (n=6, control). Using a modified Boyden chamber chemotaxis was measured towards platelet derived growth factor (PDGF) and foetal calf serum (FCS) and invasion through a Matrigel layer. MMP-2 production was quantified by ELISA and gelatin zymography.


RESULTS
chemoattractant studies demonstrated no difference in the effect of PDGF or FCS between the two populations of SMC. However, invasive studies demonstrated a significant increase in the number of migrating SMC isolated from IMV of AAA patients. Analysis of culture media extracts revealed that this difference was associated with a significant increase in production of MMP-2.


CONCLUSIONS
SMC derived from patients with AAA demonstrate increased invasive properties when compared to a control group. Increased migration appears to be due to overproduction of MMP-2. The enhanced migratory potential of these SMC may lead to extracellular matrix remodelling and subsequent medial disruption demonstrated in the aneurysmal aorta. These data further support evidence of the proteolytic role of MMP-2 in cell migration.
Department of Surgery, University of Leicester, UK.
S
S
Goodall
K E
KE
Porter
P R
PR
Bell
M M
MM
Thompson
D017544:Aortic Aneurysm, Abdominal / Q000201:enzymology* / Q000209:etiology / Q000503:physiopathology; D001672:Biocompatible Materials; D002478:Cells, Cultured; D002633:Chemotaxis / Q000502:physiology*; D003094:Collagen; D004338:Drug Combinations; D006801:Humans; D007797:Laminin; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis / Q000502:physiology*; D008642:Mesenteric Veins / Q000166:cytology; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000378:metabolism / Q000503:physiopathology*; D010982:Platelet-Derived Growth Factor; D011509:Proteoglycans
D001672:Biocompatible Materials; D004338:Drug Combinations; D007797:Laminin; D010982:Platelet-Derived Growth Factor; D011509:Proteoglycans; C059485:matrigel; D003094:Collagen; D020778:Matrix Metalloproteinase 2